1h Free Analyst Time
According to the recently published report 'C-C Chemokine Receptor Type 5 - Drugs In Development, 2022'; C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.Speak directly to the analyst to clarify any post sales queries you may have.
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation.
The report 'C-C Chemokine Receptor Type 5 - Drugs In Development, 2022' outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.
Report covers products from therapy areas Infectious Disease, Central Nervous System, Oncology, Respiratory, Gastrointestinal and Toxicology which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Coronavirus Disease 2019 (COVID-19), Multiple Sclerosis, Chronic Obstructive Pulmonary Disease (COPD), Metastatic Colorectal Cancer, Non-Alcoholic Steatohepatitis (NASH), Solid Tumor, Acute Respiratory Distress Syndrome, Alzheimer's Disease, Bladder Cancer, Bone Metastasis, Colon Carcinoma, Colorectal Cancer, Coronavirus Disease 2019 (COVID-19) Pneumonia, Diabetic Neuropathic Pain, Gastric Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Liver Cancer, Lung Cancer, Melanoma, Metastatic Pancreatic Cancer, Neuropathic Pain (Neuralgia), Non-Small Cell Lung Cancer, Opioid Induced Side Effects, Opium (Opioid) Addiction, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Post-Acute Sequelae of COVID 2019 (PASC or Long COVID), Post-Operative Pain, Testicular Cancer, Throat Cancer, Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)
- The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Overview
- C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Companies Involved in Therapeutics Development
- American Gene Technologies International Inc
- Aphios Corp
- Bristol-Myers Squibb Co
- Creative Bio-Peptides Inc
- Cytodyn Inc
- Forest Hills Partners Hong Kong Ltd
- GSK plc
- Merck & Co Inc
- Novartis AG
- Orion Biotechnology Canada Ltd
- C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Drug Profiles
- Product Description
- Mechanism Of Action
- History of Events
- AG-1105 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- APH-1701 - Drug Profile
- Product Description
- Mechanism Of Action
- BMS-813160 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Drugs to Antagonize CCR5 for Chronic Obstructive Pulmonary Disease - Drug Profile
- Product Description
- Mechanism Of Action
- DS-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DS-004 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DS-005 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- leronlimab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- maraviroc - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- maraviroc - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Monoclonal Antibody to Antagonize CCR5 for Chronic Obstructive Pulmonary Disease (COPD) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OB-002 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OB-002M - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RAP-103 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- vicriviroc - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Dormant Products
- C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Discontinued Products
- C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Product Development Milestones
- Featured News & Press Releases
- Jul 28, 2022: American Gene Technologies’ HIV Cure Clinical Trial Enters Critical Phase: Withdrawing Participants from Antiretrovirals
- Jul 19, 2022: Preclinical Data Demonstrate Potential of Creative Bio-Peptides’ Multi-Chemokine Receptor Antagonist RAP-103 to Enhance Opioid Analgesia and Inhibit Opioid-derived Dependence, Withdrawal and Respiratory Depression
- Jul 14, 2022: Preclinical data demonstrate potential of Creative Bio-Peptides’ multi-chemokine receptor antagonist RAP-103 to provide opioid sparing post-surgical pain relief and treatment for chronic pain
- Jul 11, 2022: CytoDyn highlights NIH Grant for HIV functional cure preclinical study of gene therapy based on leronlimab
- Apr 12, 2022: CytoDyn announces publication of peer-reviewed paper, “Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody leronlimab in two species”
- Mar 31, 2022: FDA places full clinical hold on CytoDyn’s Covid-19 programme
- Feb 24, 2022: American Gene Technologies advances closer to demonstrating a potential cure for HIV
- Feb 02, 2022: American Gene Technologies’ HIV clinical trial shows blood markers of efficacy in two more patients
- Jan 25, 2022: CytoDyn announces leadership transition plan to support regulatory approval and commercialization of Leronlimab
- Jan 13, 2022: CytoDyn cancels webcast and live Q/A scheduled for today
- Jan 10, 2022: Published paper indicates leronlimab shows activity against 4-class drug resistant HIV-1 from heavily treatment experienced (“HTE') subjects
- Jan 05, 2022: Leronlimab 14-week, NASH clinical trial met primary endpoint (PDFF) and secondary endpoint (cT1) for per protocol population in 350 mg weekly dose
- Dec 22, 2021: FDA provides positive response to begin CytoDyn’s Covid-19 antibody trial
- Dec 21, 2021: American Gene Technologies’ HIV clinical trial demonstrates blood markers of efficacy
- Dec 13, 2021: NASH phase 2 trial open-label portion demonstrates average 80 msec cT1 reduction in 50% of patients and reduction of nearly 50 msec in 80% of patients
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by American Gene Technologies International Inc, 2022
- Pipeline by Aphios Corp, 2022
- Pipeline by Bristol-Myers Squibb Co, 2022
- Pipeline by Creative Bio-Peptides Inc, 2022
- Pipeline by Cytodyn Inc, 2022
- Pipeline by Forest Hills Partners Hong Kong Ltd, 2022
- Pipeline by GSK plc, 2022
- Pipeline by Merck & Co Inc, 2022
- Pipeline by Novartis AG, 2022
- Pipeline by Orion Biotechnology Canada Ltd, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- American Gene Technologies International Inc
- Aphios Corp
- Bristol-Myers Squibb Co
- Creative Bio-Peptides Inc
- Cytodyn Inc
- Forest Hills Partners Hong Kong Ltd
- GSK plc
- Merck & Co Inc
- Novartis AG
- Orion Biotechnology Canada Ltd
